UK CAP ASA supplement claims: CAP Code Section 15 Rules for Food Supplements
A practical guide to reviewing food-supplement advertising through market-specific claim checks, product evidence and documented human approval.

On this page · 12 sections
- 1What UK CAP ASA supplement claims means
- 2Nutrition claims, health claims and neighbouring terms
- 3Section 15: wording, authorisation and use conditions
- 4Map the jurisdiction, product and claims framework
- 5Disease language: triggers for specialist review
- 6Review online claims as complete advertising assets
- 7A controlled workflow for reviewing supplement copy
- 8The claim file: evidence, decisions and traceability
- 9Three worked reviews: serving size, wording and markets
- 10Connect systems without losing approval boundaries
- 11ASA concerns: response records and escalation checks
- 12Release checklist and recurring failure modes
How does UK CAP Code & ASA Enforcement (Supplement Claims) apply to your shop floor?
Pick your industry and scale — Ask V5 rewrites the definition in your context, gives a worked example, and shows what V5 does on day one.
01What UK CAP ASA supplement claims means
UK CAP ASA supplement claims is a practical label for reviewing food-supplement advertising against CAP Code Section 15 and the nutrition and health claims framework relevant to the intended market.
It is an operational umbrella term—not a statutory definition, product category or approval designation. Keep five layers distinct:
- Advertising code: CAP Code Section 15 is the non-broadcast section covering food, food supplements and associated nutrition or health claims. It should not be confused with legislation.
- Applicable legislation: Regulation (EC) No 1924/2006, Article 1(2) covers nutrition and health claims in commercial communications, including food advertising. Market selection belongs in the review.
- Official reference resources: registers and guidance inform the assessment. Section 15 distinguishes the GB and EU registers; the applicable register depends on the legislation relevant to the communication.
- Recommended review practices: link proposed wording to product evidence, document the assessment and control the released version through change control. These are internal operating recommendations.
- Software support: use record-management tools to organise supporting material, not to substitute for a human advertising decision.
The practical question is whether this advertising version, for this product and market, has a documented basis for release. Claims substantiation supports that decision; the proposed workflow is an internal human review, not an ASA or government approval service.
This article does not cover broadcast advertising, medicinal-product authorisation or comprehensive supplement labelling.
02Nutrition claims, health claims and neighbouring terms
Use these as practical screening categories, not complete legal definitions. Classify the overall advertising message: testimonials, images and product names can contribute meaning that the headline alone does not convey. Record overlapping categories rather than forcing one label.
| Term | Initial review question | Relevant record | Boundary to check. |
|---|---|---|---|
| Nutrition claim | What nutritional property is being promoted? | Composition data and proposed wording | Presence, absence or quantity versus a health benefit. |
| Health claim | What health benefit is being conveyed? | Claim assessment and supporting evidence | Explicit wording and implied relationships. |
| Disease-related wording | Is disease, prevention or treatment invoked? | Flagged asset and specialist assessment | Escalate before deciding acceptability. |
| General product description | Does apparently descriptive wording imply a benefit in context? | Complete asset, including visuals | Description versus implied claim. |
| Product specification | What composition or acceptance criteria define the product? | Controlled specification | Technical criteria are not advertising permission. |
| Advertising approval | Who accepted this exact copy version for use? | Dated decision and approved asset | Approval is not scientific substantiation. |
Keep the advertising statement separate from the product specification: the former communicates to consumers; the latter records composition or acceptance criteria. A matching ingredient quantity does not, by itself, resolve the advertising review.
Scientific substantiation assesses evidence supporting the proposed statement. Claim-framework checks address eligibility, wording and use conditions for the intended market. Documented copy approval records the human decision on a specific asset version. Treat these as separate review tasks: neither a study, a framework match nor an approval signature substitutes for the other two.
03Section 15: wording, authorisation and use conditions
The Section 15 Background describes the nutrition and health claims framework as prescribing specific conditions of use associated with authorised health and nutrition claims. Review therefore needs to connect the proposed words to a claim basis and to the particular supplement—not merely to research about its ingredients.
Keep binding legislation separate from the advertising code. For nutrition claims, check the current text of Article 8(1) of Regulation 1924/2006 and its Annex for permission and conditions. Do not use Article 8 as the health-claim authorisation test. For health claims, Article 10(1) is a separate test: “Health claims shall be prohibited unless they comply with the general requirements in Chapter II and the specific requirements in this Chapter”, and the claim must also be authorised—either included in the list of authorised claims in the Annex to Commission Regulation (EU) 432/2012 or authorised for the purposes of Article 14.
At advertising-code level, CAP rule 15.7 requires supplement nutrition and health claims to be permitted or authorised under rule 15.1.1, with documentary evidence showing that the relevant conditions of use are met.
Keep three review questions separate
- Exact wording: record the proposed statement verbatim, including qualifiers and accompanying benefit language.
- Claim basis and conditions: identify the claim category, applicable provision or register entry, and each condition against which the proposal will be assessed.
- Product facts: record the formulation, relevant constituent quantities, recommended serving and supporting measurements used to assess those conditions.
This is a recommended review structure, not a prescribed form. A favourable study may inform claims substantiation, but does not itself establish the applicable claim basis or evaluate the proposed wording. An ingredient specification may support composition evidence, but does not by itself establish the finished supplement’s serving-level facts. Keep label claims and release limits distinct when selecting those facts.
Rule 15.1.1 sets the direct restriction: “Only nutrition claims listed in the applicable register may be used in marketing communications”, and only health claims listed as authorised, “or claims that would have the same meaning to the consumer”, may be used. Rule 15.2 adds that general benefit references are acceptable only if accompanied by a specific authorised health claim. Two supplement-specific boundaries then apply. Rule 15.8 says marketers “must not state or imply that a balanced or varied diet cannot provide appropriate quantities of nutrients in general”, should not encourage people to swap a healthy diet for supplementation, and may not suggest a widespread vitamin or mineral deficiency exists without well-established proof. Rule 15.9 says marketing for foods “must not claim to treat clinical vitamin or mineral deficiency”. Practical screening questions follow from these: does the copy imply ordinary diets fall short; does it present the product as a substitute for a healthy diet; does it assert a population-wide deficiency, and if so where is the well-established proof; and does any line read as treating a diagnosed deficiency rather than as an authorised claim? Use the GB nutrition and health claims register as a lookup for a GB review—not as an approval badge for the finished advertisement.
04Map the jurisdiction, product and claims framework
Make the intended market an explicit review input, not an assumption drawn from a UK brand address. As an operational control, map the territory, product classification and relevant distribution route before selecting the claims reference. Keep the advertising code, binding legislation and register reference distinct in the decision record.
The statutory register framework sits in Article 20(1) of Regulation 1924/2006: the appropriate authority must establish and maintain a nutrition and health claims register.
The advertising code’s Section 15 Background explains that the GB Register replaced the EU Register for claims made in Great Britain from 1 January 2021, while the EU Register continues to apply to claims made in Northern Ireland. Use that distinction as the starting map, not an exhaustive answer for every movement scheme.
The legislation also carries modification C1, recording application with modifications in Northern Ireland under the Windsor Framework Retail Movement Scheme legislation. Check current scope before deciding the legal and register basis for a particular GB-to-Northern-Ireland route; record the reasoning rather than silently overriding the market selection.
| Market or product situation | Starting reference | Additional scope check | Approval-record field |
|---|---|---|---|
| Great Britain | GB Register; Section 15 Background | Intended territory and current reference | Jurisdiction; register reference |
| Northern Ireland | EU Register; Section 15 Background | Distribution route; current C1 scope where relevant | Route; provision reference; market basis |
| Food supplement | CAP rule 15.7 | Product classification and applicable register | Classification; product version |
| Another food format | CAP Section 15 Background | Product-specific legislation and category scope | Food category; scope decision |
| Classification needs specialist review | Specialist assessment before claims review | Unresolved format or presentation questions | Classification rationale; reviewer; hold status |
Treat the table’s additional checks and record fields as review practice, not statutory form requirements. For a multi-territory campaign, create separate market-basis records rather than treating one register lookup as a global decision. Each record should capture jurisdiction, product classification, distribution route where relevant, provision reference, register reference and review date.
Connect that record to product master data and versioned finished-product specifications. Where format creates uncertainty, use a focused assessment such as the sterile or aseptic supplement boundary. Put changes to territories, routes, classifications and regulatory references through regulatory change management, with a named owner deciding whether earlier approvals need re-review.
05Disease language: triggers for specialist review
Use a specialist-review flag for proposed supplement advertising involving treatment, prevention, cure, named illnesses or an implied replacement for medical care. Hold fictional phrases such as “prevents colds” or “replaces prescribed treatment” for assessment before publication. This is a conservative screening control, not a complete legal classification of every phrase.
The advertising-code boundary is explicit: CAP rules 15.6–15.6.2 identify claims stating or implying that a food prevents, treats or cures human disease as unacceptable for products within Section 15’s remit.
Do not close the review merely because someone adds a disclaimer or exchanges one verb for another. Neither edit, by itself, documents how the original concern was resolved. Reassess the complete presentation, including imagery, testimonials and nearby wording, and record the reasoning behind the decision.
Route proposed disease-risk-reduction wording to a separate specialist assessment; do not treat it as interchangeable with treatment or prevention wording. Check the current text of CAP Section 15 and the applicable legislation, including Regulation (EC) No 1924/2006, for the precise disease-related claim scope.
As a practical control, retain the flagged wording, surrounding presentation, assessor, decision and replacement version. Link unresolved concerns to a quality risk register so ownership and follow-up remain visible.
07A controlled workflow for reviewing supplement copy
Use this internal workflow to turn a proposed statement into a traceable advertising decision. The responsibilities and states below are recommended operational controls, not statutory job titles or approval categories.
- Define scope. The copy owner records the product, intended market, audience, channel and planned placement. Identify the people responsible for technical evidence, regulatory review and final release before work starts.
- Capture wording. The copy owner saves the complete proposed asset, including visuals, qualifications, linked pages and creator instructions. Give it a version identifier; do not review an isolated sentence while surrounding content continues to change.
- Classify the claim. The regulatory reviewer records the screening category and rationale, using the distinctions covered above. Keep ambiguous product classification as an open review item rather than forcing it into a convenient category.
- Check the framework. The regulatory reviewer identifies the relevant market framework and claim references. Record uncertain territorial scope and incomplete conditions-of-use assessments as unresolved questions, with an owner and next action.
- Match product facts. The technical evidence owner connects the formulation, serving instructions and supporting product records to the proposal. Missing evidence remains visible; place the proposal in awaiting evidence rather than treating an assumption as confirmation.
- Approve the version. The release approver records the asset version, product version, intended market, channel and review conditions. Apply a human release gate to both approved content and actual placement, checking linked pages and creator instructions. A changed implementation returns to review.
- Monitor changes. Route formulation, serving-instruction, artwork, claims-reference, market, channel or material presentation changes through change control. Assign an owner to assess affected assets and initiate re-review before continued use is accepted.
Define states consistently: proposed means submitted; under review means assessment is active; awaiting evidence means a dependency blocks completion; approved for a specified use means accepted only within the recorded scope; rejected means not accepted; superseded means replaced by a later version; withdrawn means removed from use.
Train reviewers, publishers and external creators on these hand-offs and escalation routes. Record what each approval signifies through a clear signature meaning statement, so evidence review is not mistaken for publication authorisation.
- Define scopeRecord product, intended territory, audience and channel.
- Capture wordingInclude names, images, captions, testimonials and linked pages.
- Classify claimSeparate nutrition, health and disease-related review questions.
- Check frameworkRecord applicable provisions, register entry and use conditions.
- Match ProductCompare formulation, serving instructions and supporting quality records.
- Approve versionNamed reviewers approve wording and its placement together.
- Monitor changesReopen review when copy, product or market changes.
08The claim file: evidence, decisions and traceability
A useful claim file reconstructs why a particular advertisement was approved for a particular product and market. The following is a recommended record structure, not a prescribed legal form. Organise it around five linked entities:
- Advertising asset: assign an identifier and version; retain proposed wording, channel, intended audience and a dated publication snapshot. Preserve the complete presentation, including images and qualifications.
- Claim assessment: identify each individual claim within that asset version. Record its referenced conditions, review rationale and unresolved questions, with an owner and disposition for each question.
- Market basis: link each assessment to the intended territory, relevant framework and dated register reference used in the review. Keep the source wording alongside the reviewer’s interpretation.
- Product evidence: link the assessment to the exact formulation and serving versions reviewed. Identify supporting specifications, composition records and relevant analytical results, including their dates and product or batch scope.
- Approval decision: record reviewer identity, decision date, outcome and any use limitations. Bind the decision to the asset, claim assessments, market basis and product versions; use an identifiable record for approval traceability.
Use certificates of analysis and linked laboratory results only for the characteristics, samples and methods they cover. Likewise, a batch record supports manufacturing facts, not advertising authorisation. Note evidence limitations explicitly rather than treating a passing result as support for every statement about the product.
Set retention periods and re-review intervals through documented policy, with a rationale tied to publication history, product changes and risk. Assign an owner and next review date; do not assume one universal advertising-record retention period.
Advertising Asset
Exact content and placement submitted for review.
- asset_id
- asset_version
- channel
- content_snapshot_uri
Claim Assessment
Wording, classification and proposed conditions of use.
- claim_id
- claim_text
- claim_class
- conditions_of_use
Market Basis
Jurisdiction and dated links to applicable authority.
- market_basis_id
- jurisdiction
- provision_reference
- register_record_uri
Product Evidence
Product-specific composition and manufacturing support for review.
- evidence_id
- sku_formula_version
- serving_instruction_version
- supporting_record_uri
Approval Decision
Human outcome tied to the reviewed version.
- decision_id
- asset_version
- reviewer_id
- decision_status
- decision_timestamp
09Three worked reviews: serving size, wording and markets
These hypothetical internal-review examples illustrate operational decisions, not enforcement precedents. No authorised claim, legal eligibility threshold or ASA outcome is assumed.
Internal-review example 1: serving-size change
Assume a hypothetical supplement contains 6 mg of nutrient X per capsule, and the reviewed serving is two capsules per day. The calculation is 6 mg/capsule × 2 capsules/day = 12 mg/day. A proposed instruction changes the serving to one capsule per day: 6 mg/capsule × 1 capsule/day = 6 mg/day. The reduction is (12 − 6) ÷ 12 × 100 = 50%.
Reopen the product-facts and conditions assessment rather than carrying forward the earlier decision. The arithmetic establishes the changed daily amount; it does not establish whether any claim qualifies.
Changed input: daily serving. Unresolved decision: whether the proposed claim remains suitable. Closure record: revised serving instructions, calculation, product-facts evidence, conditions assessment and signed human disposition.
Internal-review example 2: creator wording diverges
Assume a fictional creator caption says “prevents colds”, while the brand’s submitted wording discusses a general product benefit. Neither version is treated as approved merely because it appears in a document. Capture the actual caption, accompanying visuals, product references, account, placement URL and capture time. Apply the disease-language screen covered above, flag the asset for specialist assessment and prevent further use pending a human decision.
Editing the brand’s source document alone does not establish that the published asset was corrected. Retain the replacement version and placement record, with a check of what is actually displayed; link these through the audit trail review workflow.
Changed input: published wording. Unresolved decision: withdrawal or acceptable replacement. Closure record: original capture, specialist disposition, replacement version and verified placement status.
Internal-review example 3: one creative, two markets
Assume one creative is proposed for Great Britain and Northern Ireland. Use the jurisdiction mapping above to require separate market-basis decisions within the internal workflow, plus a route-specific scope check where relevant. Shared artwork is not a substitute for recording each assessment. If either decision remains open, do not treat the creative as released for both markets.
Changed input: intended markets and distribution route. Unresolved decision: suitability for each proposed use. Closure record: market-specific basis, applicable conditions assessment, route-check outcome and human approval tied to the creative version and placements.
10Connect systems without losing approval boundaries
As an operational practice, connect the product master to specification revisions, laboratory records, controlled documents and a publishing inventory identifying each asset and destination. Use stable product, evidence and asset identifiers with explicit version references; product names and filenames alone are unreliable matching keys. These connections can use integrations or controlled manual transfers.
Assign a source-data owner to check the transferred value, unit, serving basis and version against the originating record. The advertising reviewer checks their applicability to the proposed asset; the publishing owner confirms the released version reached each intended destination.
For a broken evidence link, stale formulation reference, changed serving instruction, incorrect unit, duplicate asset or unsuccessful publication update:
- Hold the affected decision; do not treat the previous approval as covering the exception.
- Identify impacted assets, destinations and versions, including anything already live.
- Restore or replace the reference and reconcile transferred data or publishing records.
- Reassess the change and obtain a new human decision.
- Confirm the distributed version at each destination; retain failed-update and recovery records.
Keep manufacturing disposition, advertising approval and publishing status as separate fields. Record exceptions through deviation management; recurring failures may warrant corrective and preventive action with a CAPA effectiveness check.
11ASA concerns: response records and escalation checks
The ASA sanctions page explains that the CAP Compliance team can give follow-up advice and guidance, and that when a party is unwilling or unable to comply there are sanctions it can deploy depending on the circumstances. For non-compliant claims on a marketer’s own website or social accounts, the ASA can list the advertiser and the problem on a dedicated section of its website, ask search engines to remove paid-search ads linking to the offending material, place its own paid-search ads highlighting the non-compliance, and work with social media companies to have content removed. Offline, CAP can issue Ad Alerts advising media owner members to withhold services such as advertising space, and ask members to withdraw trading privileges. These are advertising-industry measures; for advertisers who persistently break the rules and do not cooperate, the ASA states it can refer them to statutory enforcement bodies such as Trading Standards. Which measure applies depends on the case, so do not predict a particular outcome.
As an internal response practice, preserve the published asset, market and placement details, underlying review decision and relevant correspondence. Assign a response owner to coordinate communications and maintain an audit trail of decisions, actions and dates. Separate immediate containment, such as pausing distribution while assessing the concern, from the later assessment of cause and corrective action.
Track instructions sent to agencies, creators and distributors, identifying the affected asset version. Obtain confirmation of any correction or withdrawal and log unresolved placements for follow-up. The worked cases above are fictional review exercises, not ASA decisions. A corrective step does not by itself settle an external matter.
12Release checklist and recurring failure modes
Use this recommended internal checklist to close the reviews described above. It is not a compliance certificate or a replacement for specialist advice. Assign an individual to each owner role before release.
| Failure mode | Release check | Named owner. |
|---|---|---|
| Unchecked market scope | Correct market basis recorded | Regulatory reviewer |
| Wording drifts from reviewed version | Final wording and context match assessment | Copy approver |
| Mismatched serving instructions | Instructions match reviewed product version | Product owner |
| Outdated product evidence | Current supporting records accessible | Evidence owner |
| Unreviewed creator content | Complete asset has named human approval | Campaign owner |
| Unresolved publication correction | Corrected published version confirmed | Publishing owner |
Before adopting the checklist, document ownership and exception handling in the review SOP, train reviewers and publishers, and retain training records. Agree a re-review trigger, such as a formula, serving, wording or market change. Keep unresolved exceptions visible; escalate them to the named approver rather than treating a completed checklist as permission to publish. Record the release decision against the exact asset version.
Frequently asked questions
Q.Does a claim associated with an ingredient approve every statement made about the finished supplement?+
No. Under CAP rule 15.1.1, health claims must be authorised on the applicable register or have the same consumer meaning. Rule 15.7 also requires documentary evidence that the supplement meets the claim’s conditions of use. This is an advertising-code test, not blanket product approval. As a review practice, connect each proposed statement to the ingredient, serving and supporting product data. Keep claims substantiation distinct from the manufacturing question of label claim versus release limit.
Q.What can a clinical study establish before the proposed wording and conditions of use are checked?+
A clinical study can provide evidence about an observed effect in the population, formulation, dose and study period examined. Reviewers should assess study design, uncertainty and relevance to the advertised supplement rather than treating a positive result as permission to publish. CAP rule 15.1.1 separately restricts health claims to authorised claims or wording with the same consumer meaning. As an evidence-review practice, distinguish controlled trial findings from real-world evidence, and document any gap between the studied product and the marketed formulation.
Q.How should reviewers assess a product name that implies a health benefit?+
Treat the name as part of the message consumers receive, alongside imagery, headlines and nearby wording. CAP’s section 15 definition includes claims that suggest or imply a relationship with health; rule 15.2 permits general health-benefit references only when accompanied by a specific authorised health claim. As a review practice, assess each placement separately: a qualifying statement visible on the product page may disappear from a search tile. Include names and thumbnails in the e-commerce review, not just the description.
Q.Can the same advertisement be released for both Great Britain and Northern Ireland?+
Potentially, but use two territorial checks rather than a single UK approval assumption. The CAP section 15 background identifies the GB register for Great Britain and the EU register for Northern Ireland. As a release practice, record the relevant entry, conditions and proposed wording for each territory. Approve shared creative only after both reviews support it; otherwise separate the versions and targeting. Coordinate this decision with supplement labelling review so advertising does not reference the wrong market’s pack.
Q.What should a brand do when a customer testimonial says the supplement prevents illness?+
As a moderation practice, hold the testimonial out of brand advertising and refer it for claims review. CAP rule 15.6.2 excludes claims that a food prevents, treats or cures human disease; it separately allows authorised disease-risk-reduction claims. Do not assume attribution to a customer changes the message. Preserve the original submission and the decision in document control. If seeking replacement wording, ask for an accurate account of the customer’s experience rather than rewriting the statement into an invented endorsement.
Q.Which advertising records need to be reconsidered when the recommended daily serving changes?+
Reconsider the claim-to-product assessment, daily nutrient calculations, supporting specifications, directions, warnings and every creative version displaying the old serving. This is a practical change-review checklist: CAP rule 15.7 requires documentary support for meeting claim conditions. For example, assuming 5 mg of a nutrient per capsule, reducing the serving from two capsules to one changes intake from 10 mg/day to 5 mg/day. Link the reassessment to recipe approval and relevant potency checks, then record which advertisements need amendment or withdrawal.
Q.How should a brand choose retention periods and re-review triggers for approved advertising?+
As a records-management practice, set a documented retention schedule by record category, market, campaign lifespan and applicable legal or contractual obligations. Keep approval decisions traceable to the exact creative and evidence versions they covered. Use the quality risk register to define triggers such as formulation changes, revised register conditions, new evidence, complaints or altered targeting. Assign an owner and review date; use management review to address overdue reassessments. Any litigation or investigation hold should override routine deletion.
Q.Who signs off the copy when the manufacturer, brand owner and marketing agency are different businesses?+
As a governance practice, agree responsibilities before drafting: the manufacturer confirms product facts, the agency identifies the exact creative and placements, and the brand owner names the person authorised to release advertising. Assign regulatory review to a competent reviewer with access to the substantiation record. Define each approval through a signature meaning statement, supported by attributable recording. Contracts should address edits after approval and withdrawal instructions. This workflow allocates tasks rather than determining legal liability; humans retain review and release decisions.
Primary sources
Want to see how UK CAP Code & ASA Enforcement (Supplement Claims) could fit into your own records and workflows? Explore the related V5 pages or talk to our team about what applies to your operation.
